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INTRODUCTION
Ovarian cancer, being the sixth most frequently
occurring cancer in the world, takes the second place
(after cervical cancer) with respect to the occurrence
of reproductive organ cancers, and is the fifth most
common cause of death due to cancer in women.
Annually over 3000 new cases are noted in Poland
(reports based on data from the National Cancer
Registry, Poland) [23].
 Since the knowledge concerning ovarian cancer
biology is still insufficient, it has become a subject
of special interest among clinicians and scientists.
The present studies are focused on the identifica-
tion of new biomarkers which could find an appli-
cation in early disease detection and monitoring, as
well as targeting therapy design.
Maspin (mammary serine protease inhibitor), a pro-
tein belonging to serpin superfamily, has been initially
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Maspin, a protein belonging to the serpin superfamily, seems to exert tumour-
-suppressive activity. Its significance in ovarian cancer prognosis is currently un-
der investigation. In the present work, immunocytochemical maspin expression
in 132 invasive epithelial ovarian carcinomas was assessed independently in the
nucleus and cytoplasm, in correlation with histopathological and clinical data.
Positive maspin expression was found in 117 cases: nuclear/cytoplasmatic in 71,
exclusive nuclear in 29, and only cytoplasmatic in 17 cases. Cytoplasmatic maspin
expression was positively correlated with tumour grade (p = 0.000), FIGO stage
(p = 0.002), and distant metastases (p = 0.000) but exhibited no significant
correlation with tumour type (p = 0.078). Nuclear maspin expression showed
negative correlation with tumour grade (p = 0.025), FIGO stage (p = 0.05),
distant metastases (p = 0.001), and cancer remission (p = 0.000) but showed no
significant relationship with the patients’ age (p = 0.948) or cancer subtype
(p = 0.261). Kaplan-Meier survival analysis showed that strong cytoplasmatic
maspin expression was correlated with shorter disease-free survival (p = 0.000)
whereas strong nuclear expression was correlated with longer survival (p = 0.000).
In Cox regression analysis, low nuclear maspin expression (score 2 and 3) remained
a significant independent prognostic factor (p = 0.001) with a relative death risk
of 5.337. The obtained results suggest that maspin expression may be a signifi-
cant marker in epithelial ovarian carcinoma prognosis with its nuclear expression
being a good prognostic factor. (Folia Morphol 2010; 69, 4: 204–212)
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identified and described as a product of a tumour-sup-
pressing gene [38]. Its expression, except for in the
mammary gland [10, 17], has been detected in numer-
ous tissues both normal and cancerous, such as pros-
tate, ovaries, testes, thymus, large and small intestine,
stomach, pancreas, and lung [18, 21, 22, 30, 31, 32].
Experiments conducted on cancers of mammary gland
and prostate suggest that the suppressive function of
maspin in cancer disease may be multidirectional.
Maspin has been shown to limit cancer cells mobility
through the inhibition of the cascade of extracellular
plasminogen activation [4, 6]. It also exhibits the capa-
bility of angiogenesis inhibition [36] and sensitisation
of cancer cells to proapoptotic factors [11].
The biological role of maspin, as well as its mecha-
nism of action in numerous cancers, has not been ful-
ly elucidated. Moreover, its clinical significance in many
cases is ambiguous or even contradictory [35]. Whereas
in some cancers (breast, prostate, stomach, and lung)
the lack or decrease in maspin expression is associat-
ed with the formation of metastases and poor clinical
prognosis, in others (pancreas and ovarian cancers) it
is strong maspin expression which correlates with the
increase in cancer invasiveness and worse survival rates.
In ovarian glands maspin expression has been detect-
ed only in cancerous tissue (where its increase was con-
nected with poor prognosis) and not in normal cells
[32]. The significance of maspin as a prognostic factor
is additionally complicated by the fact that its appear-
ance in various cellular compartments may be associ-
ated with disparate biological functions and have dif-
ferent clinical implications. In invasive breast cancers
nuclear maspin expression has been shown to corre-
late with good prognostic factors, whereas its cyto-
plasmic expression has been shown to correlate with
poor prognostic factors [20]. Similar results have been
obtained for lung cancer, where nuclear maspin ex-
pression correlated with good prognosis [15].
The aim of the present investigation was the eluci-
dation of maspin expression significance assessed in-
dependently in the nucleus and cytoplasm of invasive
epithelial ovarian cancer cells in correlation with histo-
pathological data and clinical course of the disease.
MATERIAL AND METHODS
Patients and tissue samples
Tumour specimens were obtained during routine
histopathological diagnosis (in the years 1992–2000)
from 132 women with invasive epithelial ovarian car-
cinomas. All of the samples were collected in compli-
ance with the requirements of the Institutional Review
Board for the Protection of Human Subjects. Patients
were treated at the Department of Gynaecology,
II Chair of Gynaecology and Obstetrics at the Medical
University of Wrocław, and were stu-died retrospec-
tively. The slides for histopathological studies (H&E)
were prepared from formalin-fixed paraffin wax blocks
and the specimens for immunocytochemical studies
from the adjacent cut fragments. Haematoxylin and
eosin stained slides were subjected to histopatholog-
ical evaluation by two pathologists. Tumour stage and
grade were assigned according to the International
Federation of Gynaecology and Obstetrics [28] and
Silverberg grading system [26]. Clinicopathological
variables are summarized in Table 1.
Immunohistochemistry
For immunocytochemical studies, paraffin sections
were mounted on Superfrost+ slides, dewaxed with
xylene, and gradually rehydrated. Antigen retrieval was
performed by boiling in citrate buffer (pH 6.0) for
15 min. Activity of endogenous peroxidase was blocked
by 30 min incubation in 3% H2O2. Immunocytochem-
ical reactions were performed using primary mono-
clonal mouse antibodies against human maspin (clone
G167-7, BD PharMingen San Diego, CA). The antibo-
dies were diluted 1:400 in antibody diluent with back-
Table 1. Clinicopathological features of epithelial ovarian
carcinoma patients
Patients N %
No. of cases 132 100
Age:
£ 65 63 47.7
> 65 69 52.3
Grade (G):
G1 42 31.8
G2 46 34.8
G3 44 33.3
Stage (FIGO):
I 32 24.2
II 25 18.9
III 41 31.1
IV 34 25.8
Distant metastasis:
No 57 43.2
Yes 75 56.8
Remission:
No 92 69.7
Yes 40 30.3
Histological subtype:
Endometroid 50 37.9
Serous 35 26.5
Other 47 35.6
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ground reduction (DakoCytomations). The examined
sections were incubated with primary antibodies for
one hour at room temperature. Subsequently, incu-
bations were performed with biotinylated secondary
antibodies (15 min) and with streptavidin-biotinyla-
ted peroxidase complex (15 min). Diaminobenzidine
(DAB) was used as a chromogen (LSAB+, HRP, Dako-
Cytomations). Some sections were counterstained with
Meyer’s haematoxylin, and some were not counter-
stained to obtain a better estimation of the nuclear
reaction. As a negative control of the reaction the first
specific antibodies were substituted by Primary Mouse
Negative Control (DakoCytomations).
Maspin expression was estimated semiquantita-
tively as the percentage of cells showing positive reac-
tion, using the following scale [32]: 0 points: no posi-
tive cells; 1 point: 1–5% positive cells; 2 points: 6–50%
positive cells; 3 points: > 50% positive cells. The stain-
ing intensity was rated as follows: 1 point: weak in-
tensity; 2 points: moderate intensity; 3 points: strong
intensity. The final assessment, performed as a sum of
the percentage of positive cells and the reaction in-
tensity, was categorised into four values (0–3 points):
negative reaction £ 5% stained cells independently of
the reaction intensity (0 points), weak reaction 1–2
(1 point), moderate reaction 3–4 (2 points), and strong
reaction 5–6 (3 points). Maspin expression was esti-
mated separately for the cytoplasm and nucleus of
ovarian cancer cells using the same procedure.
Statistical analysis
Statistical analyses were performed using the SPSS
for Windows version 17.0 software package (SPSS Inc.,
Chicago, IL, USA). The c2 tests were used to assess the
statistical significance of association between cytoplas-
mic or nuclear maspin expression and prognostic varia-
bles. Univariate survival analysis was done according
to the Kaplan-Meier model using the log-rank test.
Survival time was estimated in months from the date
of diagnosis to the date of death or last follow-up.
Statistical significance was defined as a probability
value less than 0.05. Finally, two Cox proportional ha-
zards models (for nuclear and cytoplasmatic expres-
sion of maspin) were fitted to the data in order to
assess the influence of maspin expression on hazards
with control over other significant predictors of ha-
zard, such as tumour stage, tumour grade, and age.
RESULTS
A positive reaction to maspin was found in 117
(88.6%) cases, whereas no reaction was observed in
15 (11.4%) cases. In the examined specimens of inva-
sive ovarian cancer, maspin expression was present in
the nucleus and/or cytoplasm. Nuclear and cytoplas-
mic distribution was observed in 71 (53.8%) cases,
exclusive nuclear expression in 29 (22.0%), and in 17
(12.9%) cases the expression was limited to the cyto-
plasm. Representative patterns of maspin expression
in ovarian cancers are demonstrated in Figure 1.
Figure 1. Immunohistochemical localisation of maspin in epithelial ovarian carcinoma. Representative immunohistochemical picture of nuclear
(A) and combined nuclear–cytoplasmic expression of maspin (B). Representative immunohistochemistry of low (C) and high (D) expression level
of maspin. The immunohistochemical signal was developed using DAB (brown). Picture C and D counterstained with haematoxylin.
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High cytoplasmic maspin expression (scores 2 and
3) was found in 68 (51.5%) cancers, whereas low or
a lack of expression (scores 0 and 1) was seen in 64
(48.5%) cancers. High nuclear maspin expression was
observed in 80 (60.6%) cases, whereas 52 (39.4%)
cases exhibited low or a lack of maspin expression.
Using the  c2 test, the relationships were examined
between cytoplasmic maspin expression and age,
tumour grade (G), disease stage (FIGO), distant
metastases, cancer remission, and the histological
subtype of the cancer. Cytoplasmic maspin immu-
noreactivity was positively associated with tumour
grade (G) (p = 0.000), FIGO disease stage (p =
= 0.002), and distant metastases (p = 0.000). No
statistical associations were found between cytoplas-
mic maspin expression and the age (p = 0.732), di-
sease remission (p = 0.081), and histological sub-
type of cancer (p = 0.078) (Table 2).
Nuclear maspin immunoreactivity was negative-
ly associated with tumour grade (G) (p = 0.025),
disease stage according to FIGO (p = 0.05), distant
metastases (p = 0.001), and cancer remission (p =
= 0.000) but showed no significant relationship with
the patients’ age (p = 0.948) or cancer subtype
(p = 0.261) (Table 3).
In Kaplan-Meier’s analysis, mean survival time
was compared between groups showing lower
(0–1) or higher (2–3) nuclear or cytoplasmic im-
munoreactivity score. Significantly shorter mean
survival times characterised the cases with higher
cytoplasmic maspin immunoreactivity (2–3) in
comparison with the patients with lower (0–1) im-
munoreactivity (p = 0.000). In contrast, longer sur-
vival times characterised the cases with higher nu-
clear immunoreactivity scores (2–3) in comparison
with patients exhibiting low immunoreactivity (0–1)
(p = 0.000). Kaplan-Meier survival curves depicting
the dependence between patient survival rates and
maspin expression are shown in Figure 2.
Other prognostic factors in univariate survival ana-
lysis were age, tumour grade, FIGO stage, distant me-
tastases, disease remission, and subtype of epithelial
ovarian carcinoma. Tumour grade, FIGO stage, and
distant metastases were significant survival factors,
whereas the patients’ age and subtype of cancer were
non-significant survival factors (Table 4).
In the multivariate survival analysis (Cox regression),
strong nuclear maspin expression (score 2 and 3) re-
mained a significant independent prognostic factor
(p = 0.001) with a relative risk of 5.337, but the
cytoplasmic strong maspin expression was not sig-
nificantly correlated with survival rates (p = 0.104;
relative risk 1.583). Other independent factors in
multivariate analysis were high tumour grade (G3)
Table 2. Association between cytoplasmic maspin expression and clinicopathological variables
Patients Negative (0) Low (1) Moderate (2) Strong (3) P (0–1) (2–3) P
Age: 0.287 0.732
£ 65 20 (45.5%) 13 (65.0%) 27 (46.6%) 3 (40.0%) 33 (51.6%) 30 (55.9%)
> 65 24 (54.5%) 7 (35.0%) 31 (53.4%) 7 (60.0%) 31 (48.4%) 38 (44.1%)
Grade (G): 0.000* 0.000
1 18 (40.9%) 10 (50.0%) 14 (24.1%) 0 (0%) 28 (43.8%) 14 (20.6%)
2 19 (43.2%) 7 (35.0%) 20 (34.5%) 0 (0%) 26 (40.6%) 20 (29.4%)
3 7 (15.9%) 3 (15.0%) 24 (41.4%) 10 (100%) 10 (15.6%) 34 (50.0%)
Stage (FIGO): 0.002 0.000
I 14 (31.8%) 6 (30.0%) 12 (20.7%) 0 (0%) 20 (31.3%) 12 (17.6%)
II 10 (22.7%) 9 (45.0%) 5 (8.6%) 1 (10.0%) 19 (29.7%) 6 (8.8%)
III 11 (25.0%) 5 (25.0%) 20 (34.5%) 5 (50.0%) 16 (25.0%) 25 (36.8%)
IV 9 (20.5%) 0 (0%) 21 (36.2%) 4 (40.0%) 9 (14.1%) 25 (36.8%)
Distant metastasis: 0.000 0.000
No 24 (54.5%) 15 (75.0%) 17 (29.3%) 1 (10.0%) 39 (60.9%) 18 (26.5%)
Yes 20 (45.5%) 5 (25%) 41 (70.7%) 9 (90%) 25 (39.1%) 50 (73.5%)
Remission: 0.041 0.081
No 31 (70.5%) 9 (45.0%) 43 (74.1%) 9 (90.0%) 40 (62.5%) 52 (76.5%)
Yes 13 (29.5%) 11 (55.0%) 15 (25.9%) 1 (10.0%) 24 (37.5%) 16 (23.5%)
Histological subtype: 0.012 0.078
Endometroid 13 (29.5%) 5 (25.0%) 29 (50.0%) 3 (30.0%) 18 (28.1%) 32 (47.1%)
Serous 16 (36.4%) 11 (55.0%) 13 (22.4%) 7 (70%) 27 (42.2%) 20 (29.4%)
Other 15 (34.1%) 4 (20.0%) 16 (27.6%) 0 (0%) 19 (29.7%) 16 (23.5%)
*Fisher’s exact test
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and high tumour stage (FIGO III–IV). The patients’
age was not a significant prognostic factor of rela-
tive risk of death (Tables 5 and 6).
DISCUSSION
There are several published studies on expression
and clinical significance of maspin in human cancers.
In this study a reversed correlation of intranuclear and
cytoplasmic maspin fractions with invasive epithelial
ovarian carcinoma stage was found, which is in agree-
ment with the earlier literature concerning ovarian,
breast, kidney, and lung cancers [7, 8, 20, 32].
Although maspin is a tumour suppressor which
inhibits cell motility, invasion, and metastasis in
Table 3. Association between nuclear maspin expression and clinicopathological variables
Patients Negative (0) Low (1) Moderate (2) Strong (3) P (0–1) (2–3) P
Age: 0.400 0.948
£ 65 17 (58.6%) 8 (34.8%) 34 (47.2%) 4 (50%) 25 (48.1%) 38 (47.5%)
> 65 12 (41.4%) 15 (65.2%) 38 (52.8%) 4 (50%) 27 (51.9%) 42 (52.5%)
Grade (G): 0.007 0.025
1 6 (20.7%) 4 (17.4%) 25 (34.7%) 7 (87.5%) 10 (19.2%) 32 (40.0%)
2 9 (34.4%) 10 (43.5%) 26 (36.1%) 1 (12.5%) 19 (36.5%) 27 (33.8%)
3 14 (43.8%) 9 (39.1%) 21 (29.2%) 0 (0%) 23 (44.2%) 21 (26.3%)
Stage (FIGO): 0.019* 0.004
I 4 (13.8%) 1 (4.3%) 25 (34.7%) 2 (25%) 5 (9.6%) 27 (33.8%)
II 3 (10.3%) 5 (21.7%) 13 (18.1%) 4 (50%) p8 (15.4%) 17 (21.3%)
III 11 (37.9%) 9 (39.1%) 20 (27.8%) 1 (12.5% 20 (38.5%) 21 (26.3%)
IV 11 (37.9%) 8 (34.8%) 14 (19.4%) 1 (12.5%) 19 (36.5%) 15 (18.8%)
Distant metastasis: 0.005 0.001
No 7 (24.1%) 6 (26.1%) 38 (52.8%) 6 (75.0%) 13 (25.0%) 44 (55.0%)
Yes 22 (75.9%) 17 (73.9%) 34 (47.2%) 2 (25%) 39 (75.0%) 36 (45.0%)
Remission: 0.000 0.000
No 27 (93.1%) 22 (95.7%) 40 (55.6%) 3 (37.5%) 49 (94.2%) 43 (53.8%)
Yes 2 (6.9%) 1 (4.3%) 32 (44.4%) 5 (62.5%) 3 (5.8%) 37 (46.3%)
Histological subtype: 0.080 0.261
Endometroid 11 (37.9%) 13 (56.5%) 26 (36.1%) 0 (0%) 24 (46.2%) 26 (32.5%)
Serous 6 (20.7%) 5 (21.7%) 19 (26.4%) 5 (62.5%) 11 (21.2%) 24 (30.0%)
Other 12 (41.4%) 5 (21.7%) 27 (37.5%) 3 (37.5%) 17 (32.7%) 30 (37.5%)
*Fisher’s exact test
Figure 2. Overall survival plot in patients with epithelial ovarian carcinoma according to the Kaplan-Meier method; A. Patients having tumours
with high maspin cytoplasmic expression (score 2 and 3) have a significantly poorer prognosis and survival rate than patients with low cyto-
plasmic expression (score 0 and 1); B. Patients with higher nuclear immunoreactivity (score 2 and 3) of maspin expression have an increased
overall survival time and an increased progression-free time than patients with low (score 0 and 1) maspin nuclear expression.
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Table 4. Kaplan-Meier survival analysis
Patients Cases Events Mean survival (Mo) SE P
Age: 0.391
£ 65 63 32 70.215 6.571
> 65 69 35 51.018 4.527
Grade (G): 0.000
1 42 8 78.839 4.186
2 46 27 64.476 6.815
3 44 32 41.208 7.647
Stage (FIGO): 0.000
1 32 2 104.938 4.151
2 25 8 93.305 8.789
3 41 25 42.747 5.219
4 34 32 24.412 5.093
Distant metastasis: 0.000
No 57 10 103.019 5.649
Yes 75 57 37.587 5.102
Remission: 0.000
No 92 66 45.521 4.720
Yes 40 1 121.175 2.789
Histological subtype: 0.146
Endometroid 50 31 57.500 7.437
Serous 35 16 71.171 8.388
Other 47 20 70.518 6.856
Maspin cytoplasmic expression: 0.001
Negative 44 18 74.466 8.101
Low 20 6 94.700 9.967
Moderate 58 37 48.174 5.959
Strong 10 6 34.800 9.612
Maspin nuclear expression: 0.000
Negative 29 25 32.793 7.021
Low 23 19 25.391 5.072
Moderate 72 22 88.639 6.047
Strong 8 1 84.375 8.068
Maspin cytoplasmic expression: 0.000
Negative/low (0–1) 64 23 83.539 6.309
Moderate/strong (2–3) 68 41 49.920 5.681
Maspin nuclear expression: 0.000
Negative/low (0–1) 52 43 31.993 5.300
Moderate/strong (2–3) 80 21 92.960 5.674
Table 6. Hazard ratios (HR) for Cox proportional hazards
model for cytoplasmic maspin expression
HR 95% CI for HR P
Age: per year 0.993 0.973–1.004 0.141
Stage (FIGO):
1–2 1.000
3–4 6.117 2.924–12.797  0.001
Grade:
1 1.000
2 2.107 0.930–4.772 0.074
3 3.978 1.783–8.874 0.001
Maspin cytoplasmic expression:
Negative/low 1.000
Moderate/strong 1.583 0.910–2.753 0.104
Table 5. Hazard ratios (HR) for Cox proportional hazards
model for nuclear maspin expression
HR 95% CI for HR P
Age: per year 0.992 0.976–1.008 0.320
Stage (FIGO):
1–2 1.000
3–4 5.193 2.365–11.401 < 0.001
Grade (G):
1 1.000
2 1.141 0.477–2.728 0.767
3 4.312 1.849–10.055 0.001
Maspin nuclear expression:
Negative/low 5.337 2.915–9.771 0.001
Moderate/strong 1.000
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some cancers, there are many contradictory reports
about its expression and prognostic significance in
other cancers [17, 38]. Downregulation of maspin
expression is associated with the progression of
breast, prostate, and colon carcinomas. On the oth-
er hand, in pancreatic, ovarian, and gastric cancers
overexpression of maspin has been shown to corre-
late with cancer progression and poor prognosis
[12]. In many studies maspin expression has been
associated with the level of cancer differentiation
and tumour grade. In pancreatic cancers, strong
expression has been observed in poorly differentia-
ted cancers (high-grade), whereas normal tissues as
well as highly differentiated cancers (low-grade) have
been characterised by a lack of maspin expression
[16]. Pemberton et al. [22] found that maspin is
a predominantly soluble cytoplasmic protein asso-
ciated with secretory vesicles at the cell surface in
mammary gland myoepithelial cells.
This study demonstrated maspin expression in
almost 90% of invasive epithelial ovarian carcino-
ma cases. Similar expression in ovarian cancers has
been exhibited immunocytochemically [32] and by
using the immunoblotting technique [25]. In the
present study, maspin staining was detected in the
nucleus and cytoplasm. More than half of the ex-
amined ovarian carcinomas (52.08%) showed
maspin expression both in the nucleus and in cyto-
plasm, 30% exclusively within the nucleus, and in
only 6.25% of cases the expression was limited to
the cytoplasm. Hence, the total nuclear expression
was observed in 82.08% of examined cancers. Sood
et al. [32] detected maspin expression in most of
the examined ovarian cancers, and in the majority
of the cases it was nuclear expression. Mohsin et
al. [20], after immunocytochemical examination of
1068 invasive breast carcinoma cases, exhibited
nuclear maspin reaction in 96% of cases, and cyto-
plasmic in 35%. Nuclear maspin localisation has also
been shown in immunocytochemical studies on
cancers of: prostate [18], lung [15], colon [5], and
pancreas [16], as well as squamous cell carcino-
mas of the larynx [19].
In this work, the results obtained from immuno-
histochemical studies separately analysing nuclear
and cytoplasmic maspin expression were compared
with clinicopathological data. Nuclear maspin over-
expression was correlated with lower tumour stage
(p = 0.004), grade (p = 0.025), and higher remis-
sion rates (p = 0.000). No correlation was found
between nuclear maspin expression and tumour type
or women’s age.
Cytoplasmic maspin expression also exhibited
statistically significant correlation with tumour grade
(p = 0.03) and FIGO stage, but this dependency
demonstrated a reversed direction in comparison
with nuclear expression: the greatest cytoplasmic
levels of maspin were observed in high-grade, poorly
differentiated cancers, and higher FIGO stage of di-
sease (especially FIGO III and IV).
Kaplan-Meier’s univariate survival analysis indicates
that patients with high nuclear maspin expression
(scores 2 and 3) have longer survival rates in compar-
ison with those showing weak or no expression. The
reversed pattern was observed in patients with high
cytoplasmic maspin expression, whose survival rates
were shorter. The performance of Cox regression anal-
ysis (multivariate) demonstrated that in the group of
patients with low or no maspin expression the risk of
death increased by over five-fold as compared with
the group characterised by an average or high maspin
expression (HR = 5.337; p = 0.001). Higher intensity
of cytoplasmic maspin expression tended to correlate
directly with risk of death; however, this effect proved
to be statistically not significant.
These results are in agreement with the data
obtained by Sood et al. [32] and Mohsin et al. [20],
who discovered that in ovarian and breast cancers
nuclear maspin expression is correlated with longer
disease-free interval in patients. Cytoplasmic stain-
ing was associated with poor prognostic factors and
shorter survival rates.
There is increasing evidence pointing to the dis-
parate functions of maspin with regard to its subcel-
lular localisation: whereas nuclear localisation is as-
sociated with good prognosis in many cancers,
maspin presence in the cytoplasm is a bad prognos-
tic factor [15]. Nuclear maspin fraction is thought to
be a biologically active form playing a substantial role
in cancer suppression, whereas the cytoplasmic frac-
tion seems to be an inactive form [9]. Maspin accu-
mulation in the cytoplasm may lead to its autoinhi-
bition through polymerisation, resulting in activity
decline [34]. This hypothesis would explain the high
cytoplasmic maspin expression in ovarian cancers as
well as its correlation with morphological and clini-
cal features of tumours indicative of poor prognosis.
Maspin function, as well as mechanisms control-
ling its expression in ovarian cancers, has not been
well explained. Studies on cell lines derived from
normal and cancerous ovarian cells suggest that
maspin expression is regulated epigenetically via
methylation of maspin gene promoter. Cytosine
methylation leads to the formation of a protein com-
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plex containing methyl binding protein which inhi-
bits gene transcription. Treatment of ovarian cells
showing no maspin expression with DNA methyl-
transferase inhibitor 5-aza-2’-deoxycytidine (5-aza-dC)
abolishes epigenetic silencing of maspin gene [24].
Some studies show that p53 protein activates
maspin expression through direct binding with the
specific promoter region (consensus binding site),
which stimulates nucleosome acetylation, chroma-
tin relaxation, and gene activation [39].
The function of nuclear maspin is hardly known.
It has been suggested that it participates in stress-
-induced apoptosis promotion, and probably affects
some gene expression. Proapoptotic maspin action
depends on the sensitisation of cells to exogenous
factors inducing death. Maspin has been demonstrat-
ed to induce proapoptotic Bax protein, probably at
the level of transcription and protein stability [14,
37]. Maspin increases the expression of transcription
factors such as E2F1, antiangiogenic thrombospon-
din, and a complex of proteins rearranging chroma-
tin SMARCA2, and decreases the expression of cy-
tokines regulating inflammatory processes and cell
proliferation [2]. Solomon et al. [29] demonstrated
that nuclear maspin expression in ovarian cancer cells
is associated with lower vascular endothelial growth
factor expression and hence with diminished cancer
vascularisation, which could explain the improved sur-
vival seen in patients with nuclear maspin expression.
Although direct molecular partners of maspin are
not well known, recent studies suggest its interac-
tion with oxidative stress-associated proteins (GST,
glutathione S-transferase), heat shock proteins, his-
tone deacetylase I (HDAC1), interferon regulatory fac-
tor 6 (IRF6), or transcription factors such as Egr1 and
CGF2 (9). Maspin interaction with HDAC leads to its
inhibition. In maspin-transfected prostate cancer cells
the increase in the expression of genes downregulat-
ed by HDAC1, such as genes encoding p21 and Bax,
has been observed [3]. Another molecule worth men-
tioning which is capable of interaction with maspin
is IRF6, the protein which probably induces transi-
tion of the cells into the G0 phase. In breast cancers
its level undergoes dynamic alteration resembling
maspin changes; similarly to maspin, IRF6 expression
decreases with cancer progression, while the induc-
tion of its expression leads to the cell cycle arrest [1].
CONCLUSIONS
In conclusion, maspin presence in two different
cellular compartments may be associated with dis-
parate function as well as with varied clinical im-
plications. Numerous previous studies have sug-
gested that nuclear maspin expression is a good
prognostic factor in cancers derived from various
organs including lung [27], mammary gland [20],
and ovaries [32]. On the other hand, cytoplasmic
maspin expression is associated with worse prog-
nosis in the development of breast [20, 33] and
lung [9, 13] cancers. The results obtained in this
work suggest that nuclear and cytoplasmic maspin
fractions may act in a reversed way in ovarian can-
cer. Positive correlation between nuclear maspin
expression and histopathological and clinical fea-
tures indicative of a good prognosis supports the
hypothesis about its being a good prognostic fac-
tor in ovarian cancer [32]. Despite the fact that the
mechanism of maspin action in ovarian cancer and
its significance in cancer onset and progression are
not explained, its expression and localisation may
have potential prognostic significance and may be
useful in planning future therapy.
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